225 related articles for article (PubMed ID: 10438473)
1. Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) beta-lactamase from Escherichia coli.
Vakulenko SB; Taibi-Tronche P; Tóth M; Massova I; Lerner SA; Mobashery S
J Biol Chem; 1999 Aug; 274(33):23052-60. PubMed ID: 10438473
[TBL] [Abstract][Full Text] [Related]
2. Structural and biochemical evidence that a TEM-1 beta-lactamase N170G active site mutant acts via substrate-assisted catalysis.
Brown NG; Shanker S; Prasad BV; Palzkill T
J Biol Chem; 2009 Nov; 284(48):33703-12. PubMed ID: 19812041
[TBL] [Abstract][Full Text] [Related]
3. A triple mutant in the Ω-loop of TEM-1 β-lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis.
Stojanoski V; Chow DC; Hu L; Sankaran B; Gilbert HF; Prasad BV; Palzkill T
J Biol Chem; 2015 Apr; 290(16):10382-94. PubMed ID: 25713062
[TBL] [Abstract][Full Text] [Related]
4. Mass spectral kinetic study of acylation and deacylation during the hydrolysis of penicillins and cefotaxime by beta-lactamase TEM-1 and the G238S mutant.
Saves I; Burlet-Schiltz O; Maveyraud L; Samama JP; Promé JC; Masson JM
Biochemistry; 1995 Sep; 34(37):11660-7. PubMed ID: 7547898
[TBL] [Abstract][Full Text] [Related]
5. Role of residues 104, 164, 166, 238 and 240 in the substrate profile of PER-1 beta-lactamase hydrolysing third-generation cephalosporins.
Bouthors AT; Dagoneau-Blanchard N; Naas T; Nordmann P; Jarlier V; Sougakoff W
Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1443-9. PubMed ID: 9494118
[TBL] [Abstract][Full Text] [Related]
6. Natural variants modify Klebsiella pneumoniae carbapenemase (KPC) acyl-enzyme conformational dynamics to extend antibiotic resistance.
Tooke CL; Hinchliffe P; Bonomo RA; Schofield CJ; Mulholland AJ; Spencer J
J Biol Chem; 2021; 296():100126. PubMed ID: 33257320
[TBL] [Abstract][Full Text] [Related]
7. Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase.
Petrosino JF; Palzkill T
J Bacteriol; 1996 Apr; 178(7):1821-8. PubMed ID: 8606154
[TBL] [Abstract][Full Text] [Related]
8. Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.
Thomson JM; Distler AM; Prati F; Bonomo RA
J Biol Chem; 2006 Sep; 281(36):26734-44. PubMed ID: 16803899
[TBL] [Abstract][Full Text] [Related]
9. The catalytic efficiency (kcat/Km) of the class A beta-lactamase Toho-1 correlates with the thermal stability of its catalytic intermediate analog.
Nitanai Y; Shimamura T; Uchiyama T; Ishii Y; Takehira M; Yutani K; Matsuzawa H; Miyano M
Biochim Biophys Acta; 2010 Apr; 1804(4):684-91. PubMed ID: 19883800
[TBL] [Abstract][Full Text] [Related]
10. The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics.
Cantu C; Palzkill T
J Biol Chem; 1998 Oct; 273(41):26603-9. PubMed ID: 9756899
[TBL] [Abstract][Full Text] [Related]
11. Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis.
Levitt PS; Papp-Wallace KM; Taracila MA; Hujer AM; Winkler ML; Smith KM; Xu Y; Harris ME; Bonomo RA
J Biol Chem; 2012 Sep; 287(38):31783-93. PubMed ID: 22843686
[TBL] [Abstract][Full Text] [Related]
12. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.
Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J
Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192
[TBL] [Abstract][Full Text] [Related]
13. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.
Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G
J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307
[TBL] [Abstract][Full Text] [Related]
14. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling.
Huletsky A; Knox JR; Levesque RC
J Biol Chem; 1993 Feb; 268(5):3690-7. PubMed ID: 8429044
[TBL] [Abstract][Full Text] [Related]
15. The Drug-Resistant Variant P167S Expands the Substrate Profile of CTX-M β-Lactamases for Oxyimino-Cephalosporin Antibiotics by Enlarging the Active Site upon Acylation.
Patel MP; Hu L; Stojanoski V; Sankaran B; Prasad BVV; Palzkill T
Biochemistry; 2017 Jul; 56(27):3443-3453. PubMed ID: 28613873
[TBL] [Abstract][Full Text] [Related]
16. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design.
Powers RA; Caselli E; Focia PJ; Prati F; Shoichet BK
Biochemistry; 2001 Aug; 40(31):9207-14. PubMed ID: 11478888
[TBL] [Abstract][Full Text] [Related]
17. Site-directed mutagenesis of beta-lactamase TEM-1. Investigating the potential role of specific residues on the activity of Pseudomonas-specific enzymes.
Lenfant F; Petit A; Labia R; Maveyraud L; Samama JP; Masson JM
Eur J Biochem; 1993 Nov; 217(3):939-46. PubMed ID: 8223651
[TBL] [Abstract][Full Text] [Related]
18. Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime.
Cantu C; Huang W; Palzkill T
J Biol Chem; 1996 Sep; 271(37):22538-45. PubMed ID: 8798421
[TBL] [Abstract][Full Text] [Related]
19. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
Stapleton PD; Shannon KP; French GL
Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
